Is RMD (ASX:RMD) Leading a Healthcare Turnaround Signal?

Highlights

• ResMed (ASX:RMD) is under close watch as ASX healthcare sentiment remains weak across the sector.

• The stock has fallen significantly over the past year while some analysts flag it below fair value estimates.

• ASX healthcare remains under pressure as investors debate whether the selloff has overshot fundamentals.

ResMed (ASX:RMD) is in focus as ASX healthcare remains under pressure, with investors debating whether the sector’s selloff has gone beyond fundamentals.

Australian healthcare shares are once again in focus, with ResMed (ASX:RMD) attracting attention as investors reassess whether the sector’s prolonged downturn has gone too far. Within a broader market shaped by shifting risk appetite across the ASX 200, healthcare names have been heavily sold off, leaving several high-quality businesses trading at levels that have prompted renewed debate about valuation versus sentiment.

As ASX healthcare continues to struggle, ResMed stands out as one of the more closely watched large-cap names in the sector.

Why ResMed is back in focus

ResMed (ASX:RMD), a global leader in sleep apnoea and respiratory care devices, has become a central reference point in discussions around ASX healthcare valuations. After a difficult year marked by sustained selling pressure, the company is now being examined through a value lens rather than a momentum one.

What has drawn attention is the growing view among some market commentators that the stock may be trading below estimated fair value. This shift in perception often emerges when share prices decline faster than underlying earnings expectations, particularly for established, cash-generating companies.

Within the broader Healthcare Stocks sector, ResMed remains one of the most globally diversified and consistently profitable names listed in Australia.

Sector-wide pressure shaping sentiment

The decline in ResMed’s share price has not occurred in isolation. ASX healthcare has faced one of its most challenging periods in recent memory, with several large-cap names falling to multi-year lows.

Multiple forces have contributed to this pressure. These include earnings revisions across the sector, shifting global macro conditions, and a broader rotation of capital into other areas of the market. In particular, energy and resources have attracted renewed attention, drawing flows away from defensive growth sectors.

Even companies with stable earnings profiles have not been immune to this broader sentiment shift, as investors reassess growth expectations across the healthcare space.

The valuation debate around RMD

The central question emerging around ResMed (ASX:RMD) is whether the recent decline reflects business fundamentals or broader market sentiment.

On one side of the debate, some analysts point to the company’s long-term demand drivers, including global respiratory health trends and an ageing population. These factors are typically associated with steady structural demand over time.

On the other side, market sentiment has been weighed down by sector-wide uncertainty, leading to compressed valuations across ASX healthcare. This creates a disconnect between perceived intrinsic value and current trading levels, which is where value-focused interest tends to emerge.

Why quality matters in downturns

Periods of sector-wide weakness often highlight the importance of business quality. In healthcare, companies with strong balance sheets, consistent cash flow generation and established global markets tend to attract increased attention when sentiment weakens.

ResMed fits within this category due to its scale and recurring demand profile. However, even high-quality companies can experience extended periods of share price pressure when broader sentiment turns negative.

This dynamic is what has fuelled ongoing debate around whether the current healthcare downturn represents a cyclical phase or a longer structural shift.

ASX healthcare under broader pressure

The performance of ASX healthcare has lagged compared with other major sectors, contributing to a re-rating across several well-known names. This has created a more cautious environment where investors are increasingly focused on earnings resilience rather than growth narratives.

In this environment, even stable performers are being re-evaluated, as market participants reassess expectations for revenue growth and margin stability.

ResMed’s position as a global healthcare technology leader means it often becomes a reference point for broader sector sentiment shifts.

What investors are watching next

Attention now turns to whether fundamentals begin to reassert themselves against sentiment-driven pricing. For ResMed (ASX:RMD), key areas of focus include:

• Demand trends in sleep and respiratory therapy devices

• Stability of operating margins

• Competitive positioning in global healthcare markets

At the same time, broader market conditions across the ASX 200 will continue to influence sector rotation and risk appetite, particularly if macroeconomic signals shift.

ResMed (ASX:RMD) sits at the centre of a broader debate about value and sentiment within ASX healthcare. While the sector has faced sustained pressure, the discussion is increasingly shifting toward whether high-quality healthcare names have been oversold relative to their long-term earnings profile.

As the market continues to reassess risk across sectors, healthcare remains one of the most closely watched areas for signs of stabilisation or further repricing.